VRX - Valeant Pharmaceuticals International, Inc.

NYSE - NYSE Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201612/31/201512/31/2014
Total Revenue9,674,00010,447,0008,206,000
Cost of Revenue2,611,0002,585,0002,236,000
Gross Profit7,063,0007,862,0005,970,000
Operating Expenses
Research Development421,000334,000246,000
Selling General and Administrative2,870,0002,972,0001,749,000
Non Recurring1,665,000772,000547,000
Others2,673,0002,257,0001,427,000
Total Operating Expenses7,629,0006,335,0003,969,000
Operating Income or Loss-566,0001,527,0002,001,000
Income from Continuing Operations
Total Other Income/Expenses Net-33,000-119,00024,000
Earnings Before Interest and Taxes-599,0001,408,0002,025,000
Interest Expense1,836,0001,563,000971,000
Income Before Tax-2,435,000-155,0001,054,000
Income Tax Expense-27,000133,000174,000
Minority Interest106,000119,000122,300
Net Income From Continuing Ops-2,409,000-312,000751,000
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-2,409,000-292,000881,000
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-2,409,000-292,000881,000